Poseida Therapeutics, Inc.
4250 Campus Point Court
Suite 700
San Diego
California
92121
United States
Website: http://poseida.com/
Email: info@poseida.com
89 articles with Poseida Therapeutics, Inc.
-
Poseida Therapeutics Reports Operational Update and Financial Results for Second Quarter and First Half of 2020
8/20/2020
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced an operational update and financial results for the quarter ended June 30, 2020 .
-
Shares of Poseida Therapeutics plunged more than 20% in premarket trading this morning after the company announced the U.S. Food and Drug Administration halted a cancer drug trial due to safety concerns.
-
Poseida Therapeutics Appoints Harry J. Leonhardt, Esq. as General Counsel
7/16/2020
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to utilizing proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today announced biotech veteran Harry J. Leonhardt, Esq. has joined the company as General Counsel and Chief Com
-
Poseida Therapeutics Announces Pricing of Initial Public Offering
7/9/2020
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to utilizing proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today announced the pricing of its initial public offering of 14,000,000 shares of its common stock at a price to the public of $16.00 per share
-
Rapha Capital Management Participates in Series D Financing for Poseida Therapeutics
6/25/2020
Rapha Capital Management, LLC ( https://raphacap.com ), an investment management firm located in Miami, Florida , through Rapha Capital Investment XI, LLC ("RCI XI") (an entity managed by Rapha Capital), participated in Poseida Therapeutics Inc.'s Series D financing, led by funds advised by Fidelity Management Research Company, LLC. RCI XI i
-
Poseida Therapeutics Raises $110 Million in Series D Financing
6/25/2020
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to utilizing proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, announced the closing of a Series D financing round, raising $110 million.
-
The company is focused on developing cell and gene therapies based on a proprietary DNA modification, gene editing and delivery technology.
-
Poseida Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer
5/20/2020
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to utilizing proprietary non-viral gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today announced the first patient has been dosed in its Phase 1 clinical trial evaluating P-PSMA-101, its au
-
Poseida Therapeutics to Present Update on Approach in Allogeneic CAR-T at Society for Immunotherapy of Cancer 34th Annual Meeting
11/5/2019
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, today announced it will present preclinical research findings during the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting on its lead allogeneic product candidate, P-BMCA-ALLO1, in multiple myeloma.
-
Poseida Therapeutics Appoints Kerry Ingalls as Chief Operating Officer
10/10/2019
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, today announced Kerry Ingalls has joined the company as Chief Operating Officer.
-
Be The Match BioTherapies® Announces Collaboration with Poseida Therapeutics to Support Development of Life-Saving Cellular Therapies
5/14/2019
Be The Match BioTherapies will provide end-to-end support services to accelerate clinical development of Poseida’s autologous BCMA and PSMA CAR-T programs
-
Malin Corporation plc: Poseida receives FDA orphan drug designation for lead candidate and FDA approval of fully outpatient dosing in Phase 2 clinical trial
5/14/2019
Malin Corporation plc. (Euronext Growth Dublin:MLC) (“Malin”), a company investing in highly innovative life sciences companies, is pleased to note that Poseida Therapeutics Inc. (“Poseida”), one of Malin’s Priority Assets, has announced the US Food and Drug Administration (“FDA”) has granted orphan drug designation to P-BCMA-101 for the treatment of relapsed and/or refractory multiple myeloma.
-
Rapha Capital Management Participates in Series C Financing for Poseida Therapeutics, Inc. Led by Novartis Pharmaceuticals
4/22/2019
Rapha Capital Management, LLC, an investment management firm located in Miami, Florida, and their associated entities announced their participation in a Series C financing for Poseida Therapeutics.
-
Swiss pharma giant Novartis supported the company’s Series C financing round with a $75 million equity investment.
-
A summary of IPOs from companies in the biotech and pharma world since January 1, 2019.
-
Teneobio and Poseida Expand Their Partnership to Develop UniDabs™ for Advanced CAR-T Therapies
8/7/2018
Teneobio, Inc., a next generation multi-specific antibody therapeutics company, and Poseida Therapeutics, Inc., a San Diego-based clinical-stage company translating best-in-class gene engineering technologies into lifesaving cell therapies, announced today a new research collaboration and licensi... -
Poseida Therapeutics Appoints Martin Giedlin, Ph.D., as Vice President, Technical Operations
2/5/2018
Dr. Giedlin brings significant expertise in cell therapy process development, manufacturing, and strategy in immunotherapies.
-
Poseida Therapeutics Announces First Patient Treated in Phase I Study of P-BCMA-101 CAR-T Stem Cell Memory Therapy in Patients With Multiple Myeloma
12/18/2017
The objective of the study is to evaluate the safety and efficacy of P-BCMA-101 in patients with relapsed/refractory multiple myeloma and determine a recommended Phase 2 dose.
-
Multiple Programs Featuring Poseida Therapeutics’ Advanced CAR-T Therapies Presented at American Society of Hematology 2017 Annual Meeting
12/11/2017
The company announced preclinical data from multiple chimeric antigen receptor T cell (CAR-T) programs in Poseida’s drug development pipeline.
-
Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101 at the American Association for Cancer Research Prostate Cancer Meeting
12/5/2017
The study was selected for oral presentation today at the American Association for Cancer Research Prostate Cancer: Advances in Basic, Translational, and Clinical Research meeting in Orlando, Florida.